首页 | 本学科首页   官方微博 | 高级检索  
     


Imaging of cellular therapies
Authors:M. Srinivas  E.H.J.G. Aarntzen  J.W.M. Bulte  W.J. Oyen  I.J.M. de Vries
Affiliation:
  • a Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, University Medical Centre, Nijmegen, The Netherlands
  • b Department of Medical Oncology, Radboud University Nijmegen Medical Centre, The Netherlands
  • c Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, Institute for Cell Engineering, the Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • d Department of Biomedical Engineering, Institute for Cell Engineering, the Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • e Department of Chemical & Biomolecular Engineering, Institute for Cell Engineering, the Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • f Cellular Imaging Section and Vascular Biology Program, Institute for Cell Engineering, the Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • g Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, The Netherlands
  • h Department of Radiology, Radboud University Nijmegen Medical Centre, The Netherlands
  • Abstract:Cellular therapy promises to revolutionize medicine, by restoring tissue and organ function, and combating key disorders including cancer. As with all major developments, new tools must be introduced to allow optimization. For cell therapy, the key tool is in vivo imaging for real time assessment of parameters such as cell localization, numbers and viability. Such data is critical to modulate and tailor the therapy for each patient. In this review, we discuss recent work in the field of imaging cell therapies in the clinic, including preclinical work where clinical examples are not yet available. Clinical trials in which transferred cells were imaged using magnetic resonance imaging (MRI), nuclear scintigraphy, single photon emission computed tomography (SPECT), and positron emission tomography (PET) are evaluated from an imaging perspective. Preclinical cell tracking studies that focus on fluorescence and bioluminescence imaging are excluded, as these modalities are generally not applicable to clinical cell tracking. In this review, we assess the advantages and drawbacks of the various imaging techniques available, focusing on immune cells, particularly dendritic cells. Both strategies of prelabeling cells before transplant and the use of an injectable label to target cells in situ are covered. Finally, we discuss future developments, including the emergence of multimodal imaging technology for cell tracking from the preclinical to the clinical realm.
    Keywords:Cell therapy   Cell therapeutics   Clinical trial   MRI   SPECT   PET   CT   Cell tracking
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号